drugset / Trial / NCT04251416
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.
Timeline
- Start
- 2020-03-17
- Primary completion
- 2026-12
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | Other |